Class Action Lawsuit Seeks Individuals and Health Plan Sponsors Who Have Overpaid for Naloxone Auto-Injector EVZIO

Frier Levitt announced today a search for individuals who purchased EVZIO and any entity that sponsored a health plan or prescription drug plan (“plan sponsor”) that included EVZIO on its “formulary” for potential legal action. Kaléo Pharma (“Kaléo”), manufacturer of EVZIO, may have been artificially inflating the price of the device and causing purchasers and plan sponsors that reimburse for the device to substantially overpay. Frier Levitt is looking for individuals to serve as class action representatives and plan sponsors to serve as plaintiffs to bring a claim for damages against Kaléo and ultimately stop any practice that results in overpayment for this critical device or harms the intended beneficiaries of the device.

Kaléo, a Virginia-based pharmaceutical company, manufactures EVZIO, the first and only FDA approved auto-injector in the administration of naloxone hydrochloride, which is used for emergency treatment of opioid overdose. Since 2014, the cost of the EVZIO injector has increased dramatically. In 2014, the price for a two pack of EVZIO was approximately $690. Today, the same two pack costs, in some cases, over $4,500. Depending on the circumstances, individuals and plan sponsors may have paid hundreds or even thousands of dollars more than they should have for a two pack of the device.

Individuals that purchased EVZIO between 2014 and today may have claims against Kaléo for improper overpayment. Frier Levitt is looking to file a class action against Kaléo challenging the substantial spike in the price of EVZIO and is looking for patients to serve as class action representatives to bring a claim for damages against Kaléo. Upon success, class action representatives are not only compensated for their loss, but also receive payment for their service as a class action representative.

Plan sponsors that paid for EVZIO between 2014 and today may also have claims against Kaléo for improper overpayment. Frier Levitt is looking for plan sponsors to serve as plaintiffs to bring a claim for damages against Kaléo.

Frier Levitt is looking to take legal action against Kaléo challenging the substantial spike in the price of EVZIO. If you are a patient or plan sponsor that paid for EVZIO between 2014 and today, you are encouraged to contact attorney Lucas W. Morgan, Esq. at lmorgan@frierlevitt.com or (973) 618-1660. 

About Frier Levitt, LLC

Frier Levitt is a national boutique healthcare law firm. Our 27 healthcare attorneys include pharmacist-lawyers, class action attorneys, trial attorneys whose practice concentrates in Healthcare and Pharmacy law. Our breadth of experience in the healthcare field provides a unique perspective to bring relief to patients unfairly charged excessive out of pocket costs to obtain EVZIO. For additional information, visit www.FrierLevitt.com.

Media Contact

Adam Toris
Marketing Director
atoris@frierlevitt.com
(973) 618-1660

Source: Frier Levitt, LLC


Categories: Healthcare, Healthcare Insurance, Law Suits, Medicine and Healthcare, Pharmaceuticals and Biotech, Healthcare and Medical News

Tags: EVZIO, Kaléo, Kaléo Pharma, Naloxone, Naloxone Auto-Injector, patient, plan sponsor


About Frier Levitt

View Website

Frier Levitt is a national boutique healthcare law firm, providing comprehensive regulatory, transactional and litigation advice to the Healthcare and Life Sciences industries.